Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.17 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)701.41K
Market Cap
$441.94M
Enterprise Value$40.12M
Total Cash (Recent Filing)$58.90M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 11, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding34,826,183
10 Day Avg. Volume1,127,159
30 Day Avg. Volume701,413
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.45
Price to Sales (P/S)0.00
P/FCF Ratio-1.27
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.33
Enterprise Value/Gross Profit0.88
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$24.60Price Target Upside93.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Delcath Systems News
PremiumCompany Announcements
Delcath Systems Announces 2025 Financial Guidance
PremiumCompany Announcements
Delcath Systems Shareholders Approve Key Amendments at MeetingBulls Say, Bears Say
Bulls Say
Market ExpansionHepzato's entrance into the Medicaid 340B program could expand uptake and adoption, far outweighing additional rebates.
Market OpportunitiesThere are large revenue opportunities ahead for Hepzato in breast and colorectal cancer, with potential market size reaching ~$2B in colorectal cancer and ~$1B in breast cancer.
Revenue GrowthDelcath reported $19.8M in total revenue for 1Q25, over 500% YoY up from $3.1M in 1Q24.
Bears Say
Pricing StrategyDelcath plans to participate in 340b program and introduce a ~23.1% discount on Hepzato sold to all 340b hospitals.
Rebate ImpactParticipating in the NDRA program is intended to expand patient access through rebates and 340B discounts to eligible hospitals.
Options Prices
Currently, No data available
---
Ownership Overview
31.28% Insiders
4.95% Mutual Funds
27.21% Other Institutional Investors
31.06% Public Companies and Individual Investors
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $7.17 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $441.94M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Aug 11, 2025 which is in 36 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on May 08, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.021 by $0.009.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is 0.03.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,826,183 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.03 in its last earnings report, beating expectations of $0.021. Following the earnings report the stock price went up 23.686%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
Delcath Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.60 (93.85% Upside)
$24.60 (93.85% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $12.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.42%
12-Months-Change
Fundamentals
Return on Equity
-29.95%
Trailing 12-Months
Asset Growth
141.89%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Delcath Systems, with strong revenue growth, an increase in active treatment centers, and positive financial metrics highlighting the quarter. However, challenges with European reimbursement and rising expenses tempered the overall sentiment.Read More>DCTH Stock 12 Month Forecast
Average Price Target
$24.60
▲(93.85%Upside)